Anti-wall teichoic antibodies and conjugates

Patent metadata

Field	Value
Publication number	US-9895450-B2
Application number	US-201514945716-A
Country	US
Kind code	B2
Filing date	Nov 19, 2015
Priority date	May 31, 2013
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

First claim

We claim:

1. A method of treating a bacterial infection comprising administering to a patient a therapeutically-effective amount of an antibody-antibiotic conjugate compound comprising an anti-wall teichoic acid (WTA) monoclonal antibody wherein the anti-wall teichoic acid monoclonal antibody binds to Staphylococcus aureus , and covalently attached by a protease-cleavable, peptide linker (L) to an antibiotic selected from clindamycin, novobiocin, retapamulin, daptomycin, GSK-2140944(gepotidacin) having the structure:

CG-400549 having the structure:

sitafloxacin, teicoplanin, triclosan, napthyridone, radezolid, doxorubicin, ampicillin, vancomycin, imipenem, doripenem, gemcitabine, dalbavancin, and azithromycin; and wherein the variable light chain (VL) of the anti-WTA monoclonal antibody comprises CDR L1 comprising the sequence of KSSQSIFRTSRNKNLLN (SEQ ID NO:99), CDR L2 comprising the sequence of WASTRKS (SEQ ID NO: 100), and CDR L3 comprising the sequence of QQYFSPPYT (SEQ ID NO:101); and the variable heavy chain (VH) of the anti-WTA antibody comprises CDR H1 comprising the sequence of SFWMH (SEQ ID NO: 102), CDR H2 comprising the sequence of FTNNEGTTTAYADSVRG (SEQ ID NO: 103), and CDR H3 comprising the sequence of GEGGLDD (SEQ ID NO:118) or GDGGLDD (SEQ ID NO:104).

2. A method of killing intracellular Staphylococcus aureus in the host cells of a Staphylococcus aureus -infected patient without killing the host cells by administering an antibody-antibiotic conjugate compound comprising an anti-wall teichoic acid (WTA) monoclonal antibody, wherein the anti-wall teichoic acid monoclonal antibody binds to Staphylococcus aureus , and covalently attached by a protease-cleavable, peptide linker (L) to an antibiotic moiety selected from clindamycin, novobiocin, retapamulin, daptomycin, GSK-2140944(gepotidacin) having the structure:

CG-400549 having the structure:

sitafloxacin, teicoplanin, triclosan, napthyridone, radezolid, doxorubicin, ampicillin, vancomycin, imipenem, doripenem, gemcitabine, dalbavancin, and azithromycin; and wherein variable light chain (VL) of the anti-WTA monoclonal antibody comprises CDR L1 comprising the sequence of KSSQSIFRTSRNKNLLN (SEQ ID NO:99), CDR L2 comprising the sequence of WASTRKS (SEQ ID NO: 100), and CDR L3 comprising the sequence of QQYFSPPYT (SEQ ID NO:101); and the variable heavy chain (VH) of the anti-WTA antibody comprises CDR H1 comprising the sequence of SFWMH (SEQ ID NO: 102), CDR H2 comprising the sequence of FTNNEGTTTAYADSVRG (SEQ ID NO: 103), and CDR H3 comprising the sequence of GEGGLDD (SEQ ID NO:118) or GDGGLDD (SEQ ID NO:104).

3. The method of claim 1 wherein the anti-wall teichoic acid (WTA) antibody binds WTA beta.

4. The method of claim 1 wherein the anti-wall teichoic acid (WTA) antibody binds to methicillin-resistant Staphylococcus aureus (MRSA).

5. The method of claim 1 wherein the anti-wall teichoic acid (WTA) antibody is a F(ab) or a F(ab′) 2 .

6. The method of claim 1 wherein the antibiotic moiety comprises a quaternary amine attached to the peptide linker.

7. The method of claim 1 wherein the antibody-antibiotic conjugate compound has the formula:
Ab-(L-abx) p
wherein:
Ab is the anti-wall teichoic acid antibody;
L is the peptide linker having the formula:
-Str-Pep-Y-

where Str is a stretcher unit covalently attached to the anti-wall teichoic acid (WTA) antibody; Pep is a peptide of two to twelve amino acid residues, and Y is a spacer unit covalently attached to the antibiotic;
abx is the antibiotic moiety; and
p is an integer from 1 to 8.

8. The method of claim 7 wherein Str has the formula:

wherein R 6 is selected from the group consisting of C 1 -C 10 alkylene-, —C 3 -C 8 carbocyclo, —O—(C 1 -C 8 alkyl)-, -arylene-, —C 1 -C 10 alkylene-arylene-, -arylene-C 1 -C 10 alkylene-, —C 1 -C 10 alkylene-, —C 3 -C 8 carbocyclo)-, —C 3 -C 8 carbocyclo)-C 1 -C 10 alkylene-, —C 3 -C 8 heterocyclo-, —C 1 -C 10 alkylene-(C 3 -C 8 heterocyclo)-, —C 3 -C 8 heterocyclo)-C 1 -C 10 alkylene-, —(CH 2 CH 2 O) r —, and —(CH 2 CH 2 O) r —CH 2 —; and r is an integer ranging from 1 to 10.

9. The method of claim 8 wherein R 6 is —(CH 2 ) 5 —.

10. The method of claim 7 wherein Pep comprises two to twelve amino acid residues independently selected from glycine, alanine, phenylalanine, lysine, arginine, valine, and citrulline.

11. The method of claim 10 wherein Pep is valine-citrulline.

12. The method of claim 7 wherein Y comprises para-aminobenzyl or para-aminobenzyloxycarbonyl.

13. The method of claim 7 wherein L is the peptide linker and has the formula:

where AA1 and AA2 are independently selected from an amino acid side chain.

14. The method of claim 13 wherein the amino acid side chain is independently selected from H, —CH 3 , —CH 2 (C 6 H 5 ), —CH 2 CH 2 CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 NHC(NH)NH 2 , —CHCH(CH 3 )CH 3 , and —CH 2 CH 2 CH 2 NHC(O)NH 2 .

15. The method of claim 13 wherein L is the peptide linker and has the formula:

16. The method antibody-antibiotic conjugate of claim 13 wherein L is the peptide linker and has the formula:

17. The method of claim 16 wherein L is the peptide linker and is selected from the formulas:

where R 7 is independently selected from H and C 1 -C 12 alkyl.

18. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:147.

19. The method of claim 1 , wherein the VL comprises the amino acid sequence of SEQ ID NO:123.

20. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:147 and the VL comprises the amino acid sequence of SEQ ID NO:123.

21. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:146 and the VL comprises the amino acid sequence of SEQ ID NO:121.

22. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:147 and the VL comprises the amino acid sequence of SEQ ID NO:145.

23. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:157 and the VL comprises the amino acid sequence of SEQ ID NO:145.

Assignees

• Genentech Inc

Inventors

• Brown Eric J
• Flygare John
• Hazenbos Wouter
• Lehar Sophie M
• Mariathasan Sanjeev
• Morisaki John Hiroshi
• Pillow Thomas H
• Staben Leanna
• Vandlen Richard
• Koefoed Klaus
• Strandh Magnus
• Andersen Peter S

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K38/12

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title

• C07K2317/624

  Disulfide-stabilized antibody (dsFv) · CPC title

• C07K2317/522

  CH1 domain · CPC title

• A61K47/6809

  Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin · CPC title